Processes for Making PD-1 / PD-L1 Inhibitors and Salts and Crystalline Forms Thereof

JP2023548859A5Inactive Publication Date: 2024-11-13INCYTE CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526986
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-05
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 2022099071000001
    Figure 2022099071000001
  • Figure 2022099071000002
    Figure 2022099071000002
  • Figure 2022099071000003
    Figure 2022099071000003
Patent Text Reader

Abstract

This application relates to processes and intermediates for the preparation of the PD-1 / PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, which PD-1 / PD-L1 inhibitors and their solid and salt forms are useful for the treatment of various diseases, including infectious diseases and cancer.
Need to check novelty before this filing date? Find Prior Art

Claims

1. Formula 1: [Formula 1] A crystalline form of a compound represented by the formula:

2. 2. The crystalline form of claim 1, wherein the compound of formula 1 or the pharma- ceutically acceptable salt thereof is a free base of the compound of formula 1.

3. 3. The crystalline form of claim 2, wherein the free base of the compound of formula 1 is a sesquihydrate.

4. 4. The crystalline form of claim 2 or 3 having Form I. (a) Form I has at least one X-ray powder diffraction (XRPD) peak selected from 7.0, 8.5, 10.0, 10.6, 14.6, 15.2, 15.8, 17.2, 20.1, 21.1, 23.9, 24.8, 26.1, 28.1, 29.6, and 30.2 degrees two theta (±0.2 degrees); (b) Form I has at least two XRPD peaks selected from 7.0, 8.5, 10.0, 10.6, 14.6, 15.2, 15.8, 17.2, 20.1, 21.1, 23.9, 24.8, 26.1, 28.1, 29.6, and 30.2 degrees two theta (±0.2 degrees); (c) Form I has at least three XRPD peaks selected from 7.0, 8.5, 10.0, 10.6, 14.6, 15.2, 15.8, 17.2, 20.1, 21.1, 23.9, 24.8, 26.1, 28.1, 29.6, and 30.2 degrees two theta (±0.2 degrees); (d) Form I has at least four XRPD peaks selected from 7.0, 8.5, 10.0, 10.6, 14.6, 15.2, 15.8, 17.2, 20.1, 21.1, 23.9, 24.8, 26.1, 28.1, 29.6, and 30.2 degrees two theta (±0.2 degrees); (e) Form I has XRPD peaks at 7.0, 8.5, 10.0, 10.6, 14.6, 15.2, 15.8, 17.2, 20.1, 21.1, 23.9, 24.8, 26.1, 28.1, 29.6, and 30.2 degrees two theta (±0.2 degrees); (f) Form I has two endothermic peaks in a differential scanning calorimetry (DSC) thermogram with an onset temperature (±3° C.) of 35° C. and a maximum temperature (±3° C.) of 68° C., and an onset temperature (±3° C.) of 161° C. and a maximum temperature (±3° C.) of 169° C.; (g) Form I is shown in FIG. has an X-ray powder diffraction (XRPD) pattern as shown in (h) Form I is shown in FIG. has a differential scanning calorimetry (DSC) thermogram as shown in (i) Form I is shown in FIG. having a thermogravimetric analysis (TGA) thermogram as shown in The crystalline form of claim 4.

6. 3. The crystalline form of claim 2 having Form II.

7. (a) Form II has at least one XRPD peak selected from 8.5, 15.0, 15.7, 17.0, 18.6, 20.2, 20.5, 21.7, 25.5, and 26.7 degrees two theta (±0.2 degrees); (b) Form II has at least two XRPD peaks selected from 8.5, 15.0, 15.7, 17.0, 18.6, 20.2, 20.5, 21.7, 25.5, and 26.7 degrees two theta (±0.2 degrees); (c) Form II has at least three XRPD peaks selected from 8.5, 15.0, 15.7, 17.0, 18.6, 20.2, 20.5, 21.7, 25.5, and 26.7 degrees two theta (±0.2 degrees); (d) Form II has at least four XRPD peaks selected from 8.5, 15.0, 15.7, 17.0, 18.6, 20.2, 20.5, 21.7, 25.5, and 26.7 degrees two theta (±0.2 degrees); (e) Form II has XRPD peaks at 8.5, 15.0, 15.7, 17.0, 18.6, 20.2, 20.5, 21.7, 25.5, and 26.7 degrees two theta (±0.2 degrees); (f) Form II has three endothermic peaks in a DSC thermogram with a maximum temperature (±3° C.) of 76° C., an onset temperature (±3° C.) of 165° C. and a maximum temperature (±3° C.) of 173° C., an onset temperature (±3° C.) of 206° C. and a maximum temperature (±3° C.) of 224° C.; (g) Form II is shown in FIG. has an XRPD pattern as shown in (h) Form II is shown in FIG. Has a DSC thermogram as shown in (i) Form II is shown in FIG. having the TGA thermogram shown in The crystalline form of claim 6.

8. 2. The crystalline form of claim 1, wherein the compound of formula 1 or the pharma- ceutically acceptable salt thereof is a methanesulfonate salt.

9. 9. The crystalline form of claim 8 having Form III. (a) Form III has at least one XRPD peak selected from 5.2, 7.5, 8.2, 8.8, 9.4, 11.6, 12.4, 13.0, 14.0, 14.8, 15.8, 16.6, 16.9, 17.3, 17.9, 19.2, 23.6, 24.5, 25.5, and 26.6 degrees 2-theta (±0.2 degrees); (b) Form III has at least two XRPD peaks selected from 5.2, 7.5, 8.2, 8.8, 9.4, 11.6, 12.4, 13.0, 14.0, 14.8, 15.8, 16.6, 16.9, 17.3, 17.9, 19.2, 23.6, 24.5, 25.5, and 26.6 degrees two theta (±0.2 degrees); (c) Form III has at least three XRPD peaks selected from 5.2, 7.5, 8.2, 8.8, 9.4, 11.6, 12.4, 13.0, 14.0, 14.8, 15.8, 16.6, 16.9, 17.3, 17.9, 19.2, 23.6, 24.5, 25.5, and 26.6 degrees two theta (±0.2 degrees); (d) Form III has at least four XRPD peaks selected from 5.2, 7.5, 8.2, 8.8, 9.4, 11.6, 12.4, 13.0, 14.0, 14.8, 15.8, 16.6, 16.9, 17.3, 17.9, 19.2, 23.6, 24.5, 25.5, and 26.6 degrees two theta (±0.2 degrees); (e) Form III has XRPD peaks at 5.2, 7.5, 8.2, 8.8, 9.4, 11.6, 12.4, 13.0, 14.0, 14.8, 15.8, 16.6, 16.9, 17.3, 17.9, 19.2, 23.6, 24.5, 25.5, and 26.6 degrees two theta (±0.2 degrees); (f) Form III has two endothermic peaks in a DSC thermogram with an onset temperature (±3° C.) of 30° C. and a maximum temperature (±3° C.) of 67° C., and an onset temperature (±3° C.) of 179° C. and a maximum temperature (±3° C.) of 202° C.; (g) Form III is shown in FIG. has an XRPD pattern as shown in (h) Form III is shown in FIG. Has a DSC thermogram as shown in (i) Form III is shown in FIG. having the TGA thermogram shown in 10. The crystalline form of claim 8 or 9.

11. A pharmaceutical composition comprising the crystalline form or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 10, and a pharma- ceutically acceptable carrier or excipient.

12. The pharmaceutical composition described in claim 11, for treating a disease or disorder associated with inhibition of PD-1 / PD-L1 interaction, wherein the disease or disorder is cancer.

13. The pharmaceutical composition described in claim 12, wherein the cancer is selected from lung cancer, small cell lung cancer, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, melanoma, bladder cancer, urethral cancer, renal cancer, clear cell renal carcinoma, and cutaneous squamous cell carcinoma.

14. 1. A process for preparing (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid (compound of formula 1), or a salt thereof, comprising: Formula B-2: [chemical 2] or a salt thereof, [C3] (In the formula, M + Li + , Na + , K + , or Cs + (It is) in the presence of Suzuki catalyst and base to obtain a compound of formula A-7: [C4] or a salt thereof, wherein R 1 But, C 1-6 is alkyl, and X 1b is a halo.

15. The process comprising: Formula B-2a: [C5] or a salt thereof, with a compound represented by formula B-3a: [C6] in the presence of Suzuki catalyst and base to obtain a compound of formula A-7a: [C7] 15. The process of claim 14, comprising forming a compound of the formula:

16. The process comprising: Formula B-2a': [C8] or a salt thereof, with a compound represented by formula B-3a: [C9] in the presence of Suzuki catalyst and base to obtain a compound of formula A-7a': [C10] 15. The process of claim 14, comprising forming a compound of the formula:

17. 1. A process for preparing (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid (compound of formula 1), or a salt thereof, comprising: Formula A-3: [C11] or a salt thereof, [C12] or a salt thereof in the presence of a base to obtain a compound represented by the formula B-2: [C13] or a salt thereof, wherein R 1 But, C 1-6 is alkyl, and X 1b and X 2b is independently a halo.

18. The process comprising: Formula B-2: [C14] or a salt thereof, [C15] (In the formula, M + Li + , Na + , K + , or Cs + (It is) in the presence of Suzuki catalyst and base to obtain a compound of formula A-7: [C16] or a salt thereof, wherein R 1 But, C 1-6 is alkyl, and X 1b The process of claim 17 , wherein is halo.

19. The process comprising: Formula A-3a: [C17] or a salt thereof, with a compound represented by formula B-1a: [C18] or a salt thereof in the presence of a base to obtain a compound represented by the formula B-2a: [C19] 20. The process of claim 17, comprising forming a compound of the formula:

20. The process comprising: Formula A-3a': [C20] or a salt thereof, with a compound represented by formula B-1a: [C21] or a salt thereof in the presence of a base to obtain a compound represented by the formula B-2a': [C22] 20. The process of claim 17, comprising forming a compound of the formula:

21. 1. A process for preparing (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid (compound of formula 1), or a salt thereof, comprising: Formula A-3: [C23] or a salt thereof, [C24] or a salt thereof to obtain a compound represented by formula A-5: [C25] or a salt thereof, wherein R 1 But, C 1-6 is alkyl, and X 2a is a halo.

22. The process comprising: Formula A-3a: [C26] or a salt thereof, with a compound represented by formula A-4a: [C27] or a salt thereof in the presence of an alkali metal halide and a base to obtain a compound represented by the formula A-5a: [C28] 22. The process of claim 21, comprising forming a compound of the formula:

23. The process comprising: a) Formula A-3a: [C29] or a salt thereof, with a compound represented by formula A-4a: [C30] or a salt thereof in the presence of an alkali metal halide and a base to obtain a compound represented by the formula A-5a: [C31] or a salt thereof; b) The above formula A-5a: [C32] or a salt thereof, [C33] or a salt thereof in the presence of a reducing agent to obtain a compound represented by the formula A-7a: [C34] or a salt thereof; c) The above formula A-7a: [C35] or a salt thereof with a Lewis acid to obtain a compound represented by the formula 1: [C36] or a salt thereof.

24. 1. A process for preparing (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid (compound of formula 1), or a salt thereof, comprising: Formula A-5: [C37] or a salt thereof, [C38] or a salt thereof in the presence of a reducing agent to obtain a compound represented by formula A-7: [C39] or a salt thereof, wherein R 1 But, C 1-6 The process wherein the alkyl group is an alkyl group.

25. The process comprising: Formula A-5: [C40] or a salt thereof, [C41] or a salt thereof in the presence of a reducing agent to obtain a compound represented by formula A-7: [C42] or a salt thereof, wherein R 1 But, C 1-6 25. The process of claim 24, wherein the alkyl group is an alkyl group.

26. The process comprising: Formula A-5a: [C43] or a salt thereof, [C44] or a salt thereof in the presence of a reducing agent to obtain a compound represented by the formula A-7a: [C45] 26. The process of claim 24 or 25, comprising forming a compound of the formula:

27. The compound of formula A-3 or the salt thereof is Formula A-1: [C46] or a salt thereof, [C47] or a salt thereof, in the presence of Suzuki catalyst and a base, X 3a But it is a halo. R 1 But, C 1-6 is alkyl, Each R 2 are independently H and C 1-6 alkyl; or Each R 2 together, optionally 1, 2, 3, or 4 independently selected C 1-4 C substituted with an alkyl group 2-3 22. The process of any one of claims 17, 18 and 21, wherein an alkylene linker is formed.

28. The process comprising: Formula A-1a: [C48] or a salt thereof, [C49] or a salt thereof in the presence of Suzuki catalyst and a base.

29. The process comprising: Formula A-1a': [50] or a salt thereof, [C51] or a salt thereof in the presence of Suzuki catalyst and a base.

30. The compound of formula 1 or the salt thereof is Formula A-7: [C52] or a salt thereof, [C53] or a salt thereof, wherein R 1 But, C 1-6 26. The process of any one of claims 14, 18, 24 and 25, wherein the alkyl group is alkyl.

31. The compound of formula 1 or the salt thereof is Formula A-7a: [C54] or a salt thereof with a Lewis acid to obtain a compound represented by the formula 1: [C55] 31. The process of claim 30, wherein the compound is prepared by a process comprising forming a compound of the formula:

32. The compound of formula 1 or the salt thereof is Formula A-7a': [C56] or a salt thereof with a base to obtain a compound represented by the formula 1: [C57] 31. The process of claim 30, wherein the compound is prepared by a process comprising forming a compound of the formula:

33. Formula A-1: [C58] or a salt thereof, comprising a compound of formula 6: [C59] or a salt thereof under oxidative conditions to form said compound of formula A-1 or said salt thereof, 1 But, C 1-6 is alkyl, and X 3a is a halo.

34. The compound of formula 6 or the salt thereof is Formula 5: [60] or a salt thereof, [61] or a salt thereof, wherein R 1 But, C 1-6 alkyl, and paraformaldehyde; X 3a The process of claim 33 , wherein is halo.

35. The compound of formula 5 or the salt thereof is Formula 4: [62] to said compound of formula 5 or a salt thereof, 3a The process of claim 34 , wherein is halo.

36. The compound of formula 4 is Formula 3: [63] or a salt thereof, with a compound represented by formula 8A: [64] in the presence of a base, with a compound of formula X 3a The process of claim 35 , wherein is halo.

37. The compound of formula 8A is Formula 8: [65] or a salt thereof, with a chlorinating agent, 3a The process of claim 36 , wherein is halo.

38. The compound of formula B-1 or the salt thereof is Formula 12: [66] or a salt thereof with a halogenating agent, 1b The process of claim 22 , wherein is halo.

39. The compound of formula A-4 or the salt thereof is Formula 14: [67] or a salt thereof to form the compound of formula A-4, 2a The process of claim 21 , wherein is halo.

40. The compound of formula 14 or the salt thereof is Formula 13: [68] or a salt thereof with a halogenating agent to form said compound of formula 14 or said salt thereof.

41. The compound of formula 13 or the salt thereof is Formula 12: [69] or a salt thereof, with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane in the presence of a Suzuki catalyst and a base to form a compound of formula 13 or said salt thereof, wherein X 1b The process of claim 40 , wherein is halo.

42. The compound of formula 12 or the salt thereof is Formula 11: [C70] or a salt thereof, with a base, 1bThe process of claim 41 , wherein is halo.

43. The compound of formula 11 or the salt thereof is Formula 10: [C71] or a salt thereof with 2,2-difluoroacetic anhydride, 1b The process of claim 42 , wherein is halo.

44. 1. A process for preparing (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a salt thereof, comprising the steps of: (a) Formula A-1a′: [C72] or a salt thereof, [C73] or a salt thereof in the presence of Suzuki catalyst and a base to obtain a compound of formula A-3a': [C74] or a salt thereof; (b) reacting the compound of formula A-3a′ or the salt thereof with a compound of formula B-1a: [C75] or a salt thereof in the presence of a base to obtain a compound represented by the formula B-2a': [C76] or a salt thereof; (c) reacting the compound of formula B-2a′ or the salt thereof with a compound of formula B-3a: [C77] in the presence of Suzuki catalyst and base to obtain a compound of formula A-7a': [C78] or a salt thereof; (d) deprotecting the compound of formula A-7a′ or the salt thereof to form the (R)-1-((7-cyano-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or the salt thereof.

45. (a) Formula A-1: [C79] or a salt thereof (wherein R 1 is C 1-6 is alkyl, and X 3a is a halo), or (b) Formula A-1a: [C80] or a salt thereof, (c) Formula A-1a': [chemical 81] or a salt thereof, (d) Formula A-3: [chemical 82] or a salt thereof (wherein R 1 is C 1-6 alkyl), or (e) Formula A-3a: [chemical 83] or a salt thereof, (f) Formula A-3a′: [chemical 84] or a salt thereof, (g) Formula A-4: [C85] or a salt thereof (wherein X 2a is a halo), or (h) Formula A-4a: [chemical 86] or a salt thereof, (i) Formula A-5: [chemical 87] or a salt thereof (wherein R 1 is C 1-6 alkyl), or (j) Formula A-5a: [C88] or a salt thereof, (k) Formula A-7: [C89] or a salt thereof (wherein R 1 is C 1-6 alkyl), or (l) Formula A-7a: [C90] or a salt thereof, (m) Formula A-7a′: [C91] or a salt thereof, (n) Formula B-2: [C92] or a salt thereof (wherein R 1 is C 1-6 is alkyl, and X 1b is a halo), or (o) Formula B-2a: [C93] or a salt thereof, (p) Formula B-2a': [C94] or a salt thereof, (q) Formula 4: [C95] or a salt thereof (wherein X 3a is a halo), or (r) Formula 5: [C96] or a salt thereof (wherein X 3a is a halo), or (s) Formula 6: [C97] or a salt thereof (wherein X 3a is halo, R 1 is t-butyl), or (t) Formula 4a: [C98] or a salt thereof, (u) Formula 5a: [C99] or a salt thereof, (v) Formula 6a: [C100] or a salt thereof, (w) Formula 11: [C101] or a salt thereof (wherein X 3a is a halo), or (x) Formula 11a: [C102] or a salt thereof, A compound selected from: